FDA Approves Zidesamtinib for Specific Type of Lung Cancer
Zidesamtinib (Jideytro) is approved for patients with ROS1-positive non-small cell lung cancer who have previously received targeted therapy.
Zidesamtinib (Jideytro) is approved for patients with ROS1-positive non-small cell lung cancer who have previously received targeted therapy.
Surgeons used small incisions and robotic instruments instead of dividing the breastbone or ribs to reduce pain and accelerate patient recovery.
Recent updates to the national lung allocation system have not eliminated regional differences in donor availability.
Insmed will present four abstracts on treprostinil palmitil inhalation powder (TPIP), being evaluated as a once-daily therapy for the treatment of patients with PAH, PH-ILD, and other rare and serious pulmonary disorders.
A study of more than 32,000 CTPA scans found that artificial intelligence and physicians agreed on pulmonary embolism results nearly 98% of the time, though human review caught cases the software missed.
A patient with advanced lung cancer and interstitial lung disease received a double-lung transplant through a clinical trial at Northwestern Medicine.
Researchers have developed a new form of CRISPR technology that destroys harmful cells instead of editing their genes, while leaving healthy tissue untouched.